BioSpace News Archive

Treatment with Erleada plus androgen deprivation therapy resulted in a 25% reduction in the risk of death compared to placebo in prostate cancer patients.

Frustrated by your job search? Does your dream employer rarely have openings? A little-known technique – the job proposal approach – can open doors for you.

Scientists from the University of Michigan have created a device that can mass-produce human embryo-like structures, according to a recent NPR report. The synthetic, living objects closely resemble a primitive form of human embryos.

The Massachusetts Biotechnology Council recently released a 2019 transportation survey for the Bay State that shows 60% of respondents would change jobs for a better commute.

AbbVie’s Mayvret won expanded approval from the U.S. Food and Drug Administration to shorten the one-daily treatment duration from 12 to eight weeks in treatment-naïve hepatitis C patients without cirrhosis and with compensated cirrhosis.

Current Chief Executive Officer Albert Bourla will succeed Read as chairman on Jan. 1, 2020 and will continue to serve as CEO.

The FDA’s latest approval for Darzalex is based on results from the Phase III CASSIOPEIA trial that showed the addition of Darzalex to VTd before and after ASCT resulted in deeper responses in patients with the blood cancer.

Pfizer announced positive top-line results from the first trial in May.

BerGenBio ASA, a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications, is to provide study updates in two poster presentations from its Phase II clinical development programme with bemcentinib, a first-in-class highly selective oral AXL inhibitor, at the European Society for Medical Oncology 2019 Congress, in Barcelona.

The cancer biotech company Alpha Tau Medical, announced the appointment of Prof. Yona Keisari as Chief Scientific Officer.